EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting the gut-liver axis in cholangiocarcinoma: mechanisms, therapeutic advances, and future directions

Lu Wang, Weiwei Qiao, Xiaowen Zhen, Yeqiong Zhang, Zhiwei Dong

Frontiers in Oncology · 12.09.2025 · 15

DOI: 10.3389/fonc.2025.1646897 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 12.09.2025. Verfasst von Lu Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostics, Second School of Clinical Medicine, Binzhou Medical University, Yantai, Shandong, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cholangiocarcinoma (CCA), a highly aggressive biliary tract malignancy, exhibits rising incidence rates and an extremely poor prognosis. Recent studies reveal that gut-liver axis dysregulation drives CCA progression through gut microbiota dysbiosis, bile acid (BA) metabolic disturbances, and immune microenvironment remodeling. Clinical evidence highlights significant alterations in the gut and biliary microbial composition of CCA patients, which correlate with tumor stage, vascular invasion, and survival outcomes. Dysregulated BA metabolism in CCA, characterized by accumulation of primary conjugated BAs, promotes tumor invasiveness via interaction with specific BA receptors and fosters an immunosuppressive microenvironment. Emerging therapeutic strategies include antibiotics for pathogenic microbiota modulation, probiotics for microbial homeostasis restoration, fecal microbiota transplantation, and BA pathway modulators. Future directions necessitate integrating synthetic biology (engineered microbiota), multi-omics, and artificial intelligence to develop precision therapies. Targeting the gut-liver axis offers novel therapeutic perspectives for CCA; however, clinical translation demands deeper mechanistic insights and standardized protocols to address challenges such as microbiota heterogeneity and receptor signaling duality.

Schlagwörter

Stichwörter der Autor:innen

bile saltcholangiocarcinomaclinical translationdysbiosisgut microbiotagut-liver axistherapy

Autor:innen und Institutionen

  • Department of Diagnostics, Second School of Clinical Medicine, Binzhou Medical University, Yantai, Shandong, China.
  • Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.

Zitieren

APA

Wang, L., Qiao, W., Zhen, X., Zhang, Y., & Dong, Z. (2025). Targeting the gut-liver axis in cholangiocarcinoma: mechanisms, therapeutic advances, and future directions. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1646897

Vancouver

Wang L, Qiao W, Zhen X, Zhang Y, Dong Z. Targeting the gut-liver axis in cholangiocarcinoma: mechanisms, therapeutic advances, and future directions. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1646897

BibTeX
@article{Wang2025,
  author = {Wang, Lu and Qiao, Weiwei and Zhen, Xiaowen and Zhang, Yeqiong and Dong, Zhiwei},
  title = {Targeting the gut-liver axis in cholangiocarcinoma: mechanisms, therapeutic advances, and future directions},
  journal = {Frontiers in Oncology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fonc.2025.1646897}
}
Kostenlos starten →